# How Revolution Medicines (RVMD) compares with the whole market and its popular alternatives

> Source: EasyCompare research, https://easycompare.io/research/rvmd
> Data as of October 20, 2026. Total returns include reinvested dividends. Past performance does not predict future results; nothing here is investment advice.

Built by QuantCommons' quantitative engine, this page is about relative opportunity, not data on RVMD alone. It places RVMD (Revolution Medicines, Inc.) against 18 popular alternatives, its neighboring categories and the entire market of over 10,000 U.S.-listed stocks and ETFs, and surfaces what has done better on consistent outperformance, return for the risk taken, behavior in real market crashes and diversification. The result is a clearer view of where RVMD stands in the market, and of the alternatives worth a closer look.

Period covered: RVMD's full trading record, from February 2020 through September 2026. The crash tests reach back to 2000 using older funds and the S&P 500. All returns include reinvested dividends. Data as of October 20, 2026.

## Key findings

- **Right now:** RVMD has run far ahead of the market, rising 34.4% over the past 6 months against 9.1% for the S&P 500 and 11.2% for the Nasdaq 100. Not every peer went the same way. Over the past 6 months, IOVA (Iovance Biotherapeutics) rose 293% and COGT (Cogent Biosciences) fell 15.6%.
- **Stock or market?:** More than an industry move: RVMD rose 9.0% over the past 3 months, against 1.5% for the biotechnology ETF XBI (State Street SPDR S&P Biotech ETF). The S&P 500 rose 3.9%. Its biotechnology peers did not move as one over the past 3 months: IOVA (Iovance Biotherapeutics) rose 196%, while COGT (Cogent Biosciences) fell 18.4%.
- **Past 1 to 3 years:** Over the past year, RVMD rose 264% against 15.8% for the S&P 500 and 17.9% for the Nasdaq 100. The same gap shows up over 3 years (603% against 89.3%). RVMD finished ahead of the S&P 500 in both 2024 and 2025.
- **Long term:** RVMD turned $10,000 into $73,000 over the past 5 years, against $18,200 in the S&P 500. RVMD's 5-year return of 630% puts it ahead of 98% of the stocks worth at least $300 million with that much history. The S&P 500 returned 81.7%.
- **In a crash:** The 2022 bear market took 46.5% off RVMD, against 24.5% for the S&P 500. That was more than KRYS (Krystal Biotech, 33.4%) but less than KYMR (Kymera Therapeutics, 77.4%).
- **Diversification:** Over 5 years, RVMD's beta versus the S&P 500 was 1.39: in the S&P 500's rising months it gained about twice as much as the index, and in falling months it lost 89% as much. RVMD is some diversification, but not a hedge: a correlation of 0.42 with the S&P 500 over 5 years and 0.44 with the total US market, more closely than 56% of stocks worth at least $300 million.
- **Better options**
  - **Nearby categories and themes:** KNSA (Kiniksa Pharmaceuticals International, biotechnology) earned more than RVMD with less volatility over the past 5 years: 50.2% a year at 53.7% volatility, against 48.8% a year at 62.1%.
  - **Whole market:** Few investments have done better on both counts: only 27 of the 3,633 stocks and funds worth at least $500 million earned more than RVMD with less volatility over the past 5 years, among them NVDA (NVIDIA), MU (Micron Technology) and DELL (Dell Technologies).

## How much would $10,000 in RVMD have grown?

This chart tracks a hypothetical $10,000 investment in RVMD over the past 6 years, with dividends reinvested, alongside the same amount in the S&P 500, investments that ended ahead of RVMD over the same span and RVMD's popular alternatives, among those that traded for the entire period.

- $10,000 invested in RVMD at the end of September 2020 would have grown to $58,983 by September 2026, more than the $24,691 it would have become in SPY, an S&P 500 fund.
- Five of the eight other investments on the chart ended ahead of RVMD, and FIX finished highest, at $329,952.

## RVMD at a glance

This section summarizes the key facts about the stock, its returns over periods from one to ten years and the risk it has carried, with dividends reinvested throughout.

- RVMD's deepest decline since it began trading in 2020 was 73.3%, from February 2021 to May 2022. It took about two years from the low to climb back to its old high.
- Over five full calendar years, RVMD's best was 2025, when it returned 82.1%, and its worst was 2021, when it lost 36.4%. It lost money in two of those years.
- RVMD is 11.1% below its all-time high.

- Type: Stock, Healthcare (Biotechnology)
- Trading since: February 13, 2020
- Market value: $42B
- Volatility (5 years): 62.1%; Sharpe ratio: 0.95
- Worst decline ever: −73.3%, from February 8, 2021 to May 12, 2022; back at its high by November 1, 2024

| Period | RVMD total return |
| --- | --- |
| 1 month | +2.0% |
| 3 months | +9.0% |
| 6 months | +34.4% |
| year to date | +149% |
| 1 year | +264% |
| 3 years | +603% |
| 5 years | +630% |

## RVMD against the whole market

Where RVMD ranks among every stock and fund, and what across the market has done better.

### How does RVMD rank among all stocks?

This section ranks RVMD on return, volatility, risk-adjusted return and worst decline against every stock worth at least $300 million with enough history.

- RVMD's 1-year return ranks in the top 1% of the 3,287 stocks worth at least $300 million with 1 year of history.
- RVMD is among the more volatile stocks: its price swings rank in the bottom 19% of the 2,893 stocks worth at least $300 million, where the top is the calmest.

| Measure | RVMD | Rank |
| --- | --- | --- |
| 1-year return | +264% | 21 of 3,287 (top 1%) |
| 3-year return | +603% | 77 of 3,017 (top 3%) |
| 5-year return | +630% | 49 of 2,893 (top 2%) |
| Volatility, 5 years | 62.1% | 2,348 of 2,893 (top 82%) |
| Sharpe ratio, 5 years | 0.95 | 131 of 2,893 (top 5%) |

### What has beaten RVMD on both return and risk?

Each dot is an investment, placed by how much it earned a year over the past 5 years (higher is better) and how much its price swung, its volatility (further left is calmer).

- 27 stocks worth at least $500 million sit in the green region: each earned more than RVMD over the past 5 years with smaller price swings. That is fewer than 1% of the 3,633 screened. Few investments beat it on both counts.
- Among those with at least half RVMD's swings, FIX has the best return for its risk: 77.0% a year at 46.7% volatility, 25% less than RVMD's 62.1%, and a Sharpe ratio (return above cash per unit of volatility) of 1.46 against 0.95 for RVMD. BELFB earned the most, 78.0% a year, while still swinging less than RVMD (52.1% against 62.1%).
- None of RVMD's popular alternatives made it, but KNSA (biotechnology) did: 50.2% a year at 53.7% volatility, 14% less than RVMD's 62.1%.

### Is there a better investment than RVMD?

The table below lists investments that beat RVMD over the past 5 years on at least one of these measures: a higher annual return with lower volatility, a higher annual return at similar volatility, a similar return with lower volatility, a higher Sharpe ratio with a smaller worst decline, a higher total return in most periods from 3 months to 10 years, or smaller losses in recent market crashes.

- Looking beyond its popular alternatives, KNSA (biotechnology) earned more than RVMD with less volatility over the past 5 years: 50.2% a year at 53.7% volatility, against 48.8% a year at 62.1%.
- Few investments have done better on both counts: only 27 of the 3,633 stocks and funds worth at least $500 million earned more than RVMD with less volatility over the past 5 years, among them NVDA, MU and DELL.

The 15 strongest of 27 investments that beat RVMD over the past 5 years, out of 3,633 stocks and funds worth at least $500 million.

| Investment | Group | Annual return (5 years) | Volatility | Sharpe | Worst decline (10 years) | 5Y return | Correlation with RVMD | Better on |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| RVMD: Revolution Medicines, Inc. (this page) |  | +48.8% | 62.1% | 0.95 | −73.3% | +630% |  |  |
| [MU](https://easycompare.io/research/mu): Micron Technology, Inc. | Semiconductors | +68.1% | 57.1% | 1.20 | −57.6% | +1,244% | 0.33 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Higher return in most periods |
| [DELL](https://easycompare.io/research/dell): Dell Technologies Inc. | Computer Hardware | +55.2% | 54.4% | 1.08 | −59.6% | +800% | 0.17 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Higher return in most periods |
| [FIX](https://easycompare.io/research/fix): Comfort Systems USA, Inc. | Engineering & Construction | +77.0% | 46.7% | 1.46 | −49.7% | +1,636% | 0.39 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Smaller losses in recent crashes |
| INSW: International Seaways, Inc. | Oil & Gas | +56.5% | 40.5% | 1.31 | −57.4% | +839% | -0.06 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Smaller losses in recent crashes |
| [NVDA](https://easycompare.io/research/nvda): NVIDIA Corporation | Semiconductors | +58.0% | 51.9% | 1.14 | −66.3% | +884% | 0.25 | Higher return, lower volatility; Higher Sharpe, smaller worst decline |
| FRO: Frontline Plc | Oil & Gas | +52.6% | 49.7% | 1.10 | −52.0% | +726% | -0.06 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Smaller losses in recent crashes |
| AGX: Argan, Inc. | Engineering & Construction | +53.5% | 54.1% | 1.06 | −56.7% | +751% | 0.38 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Smaller losses in recent crashes |
| TRMD: TORM plc | Marine Shipping | +54.3% | 45.9% | 1.18 | −60.6% | +776% | -0.04 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Smaller losses in recent crashes |
| TNK: Teekay Tankers Ltd. | Marine Shipping | +50.5% | 45.1% | 1.14 | −63.4% | +673% | -0.16 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Smaller losses in recent crashes |
| [STX](https://easycompare.io/research/stx): Seagate Technology Holdings plc | Computer Hardware | +57.4% | 48.7% | 1.18 | −57.0% | +866% | 0.44 | Higher return, lower volatility; Higher Sharpe, smaller worst decline |
| [VST](https://easycompare.io/research/vst): Vistra Corp. | Independent Power Producers | +53.4% | 48.6% | 1.13 | −53.3% | +748% | 0.08 | Higher return, lower volatility; Higher Sharpe, smaller worst decline |
| IESC: IES Holdings, Inc. | Engineering & Construction | +58.5% | 58.0% | 1.09 | −54.3% | +900% | 0.47 | Higher return, lower volatility; Higher Sharpe, smaller worst decline |
| [MPC](https://easycompare.io/research/mpc): Marathon Petroleum Corporation | Oil & Gas | +51.2% | 33.4% | 1.41 | −79.7% | +690% | -0.08 | Higher return, lower volatility |
| [PBR-A](https://easycompare.io/research/pbr-a): Petróleo Brasileiro S.A. - Petrobras | Integrated Oil & Gas | +51.8% | 37.5% | 1.31 | −71.7% | +705% | -0.03 | Higher return, lower volatility |
| LPG: Dorian LPG Ltd. | Oil & Gas Midstream | +54.6% | 43.6% | 1.22 | −62.9% | +783% | -0.11 | Higher return, lower volatility; Higher Sharpe, smaller worst decline |

## RVMD against its popular alternatives

The investments people most often weigh against RVMD, compared period by period and year by year.

### How do RVMD's risk and return compare with its alternatives?

This map plots each investment's annual return over the past 5 years against its volatility, the size of its typical price swings.

- None of the 18 popular alternatives earned more than RVMD over the past 5 years with smaller price swings, so every higher return on the map came with a bumpier ride.
- 12 of the 18 popular alternatives earned less than RVMD over the past 5 years while swinging more, the weaker corner of the map.
- Over the past 5 years, RVMD returned 48.8% a year, more than the S&P 500's 12.7%, with higher volatility (62.1% against 17.1%).

### Has RVMD consistently beaten its popular alternatives?

This section compares RVMD with the investments people most often weigh against it, checking each one over seven periods from one month to five years.

- None of the 18 popular alternatives outperformed RVMD in at least 3 of 5 short-term and 2 of 2 long-term timeframes. The closest was KYMR.
- GILD earned more for the risk it took than RVMD (a higher Sharpe ratio) and fell less in its worst decline of the past 10 years.

| Investment | 1Y return | 3Y return | 5Y return | Periods ahead of RVMD | Verdict | Sharpe |
| --- | --- | --- | --- | --- | --- | --- |
| RVMD: Revolution Medicines, Inc. (this page) | +264% | +603% | +630% |  |  | 0.95 |
| KYMR: Kymera Therapeutics, Inc. | +87.5% | +834% | +116% | 0/5 short-term, 1/2 long-term |  | 0.56 |
| IOVA: Iovance Biotherapeutics, Inc. | +541% | +346% | −42.4% | 5/5 short-term, 0/2 long-term |  | 0.36 |
| [ILMN](https://easycompare.io/research/ilmn): Illumina, Inc. | +169% | +130% | −33.3% | 3/5 short-term, 0/2 long-term |  | 0.06 |
| [GILD](https://easycompare.io/research/gild): Gilead Sciences, Inc. | +30.3% | +121% | +180% | 2/5 short-term, 0/2 long-term |  | 0.95 |
| [AMGN](https://easycompare.io/research/amgn): Amgen Inc. | +48.7% | +72.2% | +145% | 2/5 short-term, 0/2 long-term |  | 0.85 |
| [TMO](https://easycompare.io/research/tmo): Thermo Fisher Scientific Inc. | +26.8% | +49.5% | +15.1% | 2/5 short-term, 0/2 long-term |  | 0.24 |
| ERAS: Erasca, Inc. | +494% | +559% | −24.1% | 2/5 short-term, 0/2 long-term |  | 0.35 |
| SDGR: Schrödinger, Inc. | +6.5% | +6.5% | −58.2% | 2/5 short-term, 0/2 long-term |  | 0.06 |
| [MRK](https://easycompare.io/research/mrk): Merck & Co., Inc. | +76.8% | +58.3% | +113% | 1/5 short-term, 0/2 long-term |  | 0.74 |
| RXRX: Recursion Pharmaceuticals, Inc. | −45.2% | −38.7% | −80.2% | 1/5 short-term, 0/2 long-term |  | 0.10 |
| FATE: Fate Therapeutics, Inc. | +33.8% | +3.0% | −96.5% | 1/5 short-term, 0/2 long-term |  | -0.23 |
| KRYS: Krystal Biotech, Inc. | +66.1% | +199% | +565% | 0/5 short-term, 0/2 long-term |  | 0.79 |
| COGT: Cogent Biosciences, Inc. | +92.6% | +254% | +269% | 0/5 short-term, 0/2 long-term |  | 0.68 |
| KURA: Kura Oncology, Inc. | −0.1% | +20.7% | −42.1% | 0/5 short-term, 0/2 long-term |  | 0.14 |
| CRSP: CRISPR Therapeutics AG | −32.6% | +29.2% | −49.3% | 0/5 short-term, 0/2 long-term |  | 0.08 |
| BEAM: Beam Therapeutics Inc. | −18.6% | +40.9% | −73.5% | 0/5 short-term, 0/2 long-term |  | 0.01 |
| NTLA: Intellia Therapeutics, Inc. | −57.7% | −55.6% | −90.8% | 0/5 short-term, 0/2 long-term |  | -0.22 |
| ARVN: Arvinas, Inc. | −21.2% | −48.3% | −91.0% | 0/5 short-term, 0/2 long-term |  | -0.34 |

### How did RVMD do year by year?

This table shows each investment's total return in every full calendar year since 2021, along with where RVMD ranked among its popular alternatives each year.

- RVMD finished ahead of the S&P 500 in three of its five full calendar years, and ahead of it in each of the last two.
- Among its popular alternatives, KYMR came out ahead of RVMD most often, in three of the five years both traded.
- Ranked against its popular alternatives each year, RVMD finished in the top quarter in two of five years and in the bottom quarter in no. In 2025, it ranked 3 of 19.

| Year | RVMD | SPY |
| --- | --- | --- |
| 2025 | +82.1% | +17.7% |
| 2024 | +52.5% | +24.9% |
| 2023 | +20.4% | +26.2% |
| 2022 | −5.4% | −18.2% |
| 2021 | −36.4% | +28.7% |

## Risk and diversification

How RVMD has fallen, how it held up in crashes beside the S&P 500 and its popular alternatives, and what moves independently of it.

### What were RVMD's worst declines?

A drawdown is the decline from a peak to the lowest point before a new high.

- In all five of RVMD's worst declines, the S&P 500 held up better over the same dates.
- Not every decline was the market's doing: RVMD fell 73.3% from February 2021 to May 2022, while the S&P 500 rose 2.1%.
- The slowest recovery came after RVMD fell 73.3% from February 2021 to May 2022; it did not regain that peak until November 2024, two years later.

| Decline | Peak | Low | Back at the high | SPY over the same dates | Market event |
| --- | --- | --- | --- | --- | --- |
| −73.3% | February 8, 2021 | May 12, 2022 | November 1, 2024 | +2.1% | 2022 bear market |
| −48.6% | November 11, 2024 | April 8, 2025 | November 6, 2025 | −16.6% |  |
| −42.5% | June 22, 2020 | July 30, 2020 | October 6, 2020 | +4.3% |  |
| −42.3% | March 4, 2020 | April 1, 2020 | May 5, 2020 | −20.9% | Covid crash |
| −33.6% | October 16, 2020 | October 30, 2020 | February 2, 2021 | −6.0% |  |

### How did RVMD do in stock market crashes?

This section measures how far RVMD, the S&P 500 and each alternative fell from peak to trough during every major market crash since 2000.

- RVMD fell further than the S&P 500 in all three crashes it has traded through. The clearest case was the 2022 bear market, when RVMD fell 46.5% and the S&P 500 fell 24.5%.
- Among its popular alternatives, GILD held up best, falling less than RVMD in all three crashes they both traded through.
- RVMD began trading after the 2008 financial crisis, but five of its popular alternatives lived through it. The mildest fall among them was AMGN's 31.3%, against 55.2% for the S&P 500.

| Crash | Dates | RVMD fall | SPY fall |
| --- | --- | --- | --- |
| Dot-com bust | March 10, 2000 to October 9, 2002 | not trading | −47.5% |
| Global financial crisis | October 9, 2007 to March 9, 2009 | not trading | −55.2% |
| Flash crash | May 6, 2010 to May 7, 2010 | not trading | −1.5% |
| Euro debt crisis | July 22, 2011 to October 3, 2011 | not trading | −17.9% |
| China devaluation & oil rout | August 10, 2015 to February 11, 2016 | not trading | −12.8% |
| Volmageddon | February 2, 2018 to February 9, 2018 | not trading | −6.5% |
| Q4 2018 selloff | September 21, 2018 to December 24, 2018 | not trading | −19.3% |
| COVID crash | February 19, 2020 to March 23, 2020 | −41.3% | −33.7% |
| 2022 bear market | January 4, 2022 to October 12, 2022 | −46.5% | −24.5% |
| SVB / regional bank stress | March 8, 2023 to March 13, 2023 | −9.5% | −3.4% |

### How closely does RVMD move with the S&P 500?

Upside capture measures how much of the S&P 500's gains an investment kept in the months the market rose, and downside capture how much of its losses it took in the months the market fell.

- Over the past 5 years, RVMD captured 191% of the S&P 500's gains in rising months and 89% of its losses in falling months, with a beta of 1.39. Its share of the market's gains was larger than its share of the losses.
- Four of the 18 popular alternatives had a higher capture ratio (upside capture divided by downside capture) than RVMD's 2.15, led by KRYS, GILD and MRK.

Measured over the past 5 years of monthly returns against SPY.

| Investment | Upside capture | Downside capture | Beta |
| --- | --- | --- | --- |
| RVMD: Revolution Medicines, Inc. (this page) | 191% | 89.0% | 1.39 |
| KYMR: Kymera Therapeutics, Inc. | 153% | 189% | 1.97 |
| IOVA: Iovance Biotherapeutics, Inc. | 27.0% | 111% | 0.74 |
| [ILMN](https://easycompare.io/research/ilmn): Illumina, Inc. | 113% | 242% | 1.42 |
| [GILD](https://easycompare.io/research/gild): Gilead Sciences, Inc. | 73.0% | 17.0% | 0.32 |
| [AMGN](https://easycompare.io/research/amgn): Amgen Inc. | 76.0% | 34.0% | 0.41 |
| [TMO](https://easycompare.io/research/tmo): Thermo Fisher Scientific Inc. | 102% | 160% | 0.88 |
| ERAS: Erasca, Inc. | 67.0% | 165% | 0.61 |
| SDGR: Schrödinger, Inc. | 83.0% | 215% | 1.62 |
| [MRK](https://easycompare.io/research/mrk): Merck & Co., Inc. | 73.0% | 31.0% | 0.20 |
| RXRX: Recursion Pharmaceuticals, Inc. | 17.0% | 237% | 1.04 |
| FATE: Fate Therapeutics, Inc. | 74.0% | 493% | 2.50 |
| KRYS: Krystal Biotech, Inc. | 135% | 11.0% | 0.49 |
| COGT: Cogent Biosciences, Inc. | 161% | 120% | 0.31 |
| KURA: Kura Oncology, Inc. | 50.0% | 158% | 0.47 |
| CRSP: CRISPR Therapeutics AG | 96.0% | 253% | 1.75 |
| BEAM: Beam Therapeutics Inc. | 89.0% | 306% | 2.19 |
| NTLA: Intellia Therapeutics, Inc. | 18.0% | 318% | 1.79 |
| ARVN: Arvinas, Inc. | 46.0% | 357% | 1.79 |

### What diversifies RVMD?

Correlation measures how closely two investments move together, on a scale from 1 (in lockstep) through 0 (unrelated) to -1 (in opposite directions).

- Moving a fifth of the money in RVMD into MPC would have cut the portfolio's volatility by 20% over the past 5 years and raised its annual return (+49.5% for RVMD alone, +53.7% for the mix).
- MPC made money in two of the two calendar years in which RVMD lost money.
- Among large ETFs, LVHI, DXJ and EMLP have moved largely independently of RVMD over the past 5 years, with correlations of 0.26 or lower, and each still earned a positive 5-year return.

| Investment | Correlation with RVMD | 5Y return | Volatility | Sharpe | Rose in RVMD's 2 down years |
| --- | --- | --- | --- | --- | --- |
| LVHI: Franklin International Low Volatility High Dividend Index ETF | 0.17 | +119% | 11.1% | 1.48 | 2 of 2 |
| DXJ: WisdomTree Japan Hedged Equity Fund | 0.19 | +225% | 19.1% | 1.34 | 2 of 2 |
| EMLP: First Trust North American Energy Infrastructure Fund | 0.26 | +101% | 14.5% | 1.04 | 2 of 2 |
| HDV: iShares Core High Dividend ETF | 0.21 | +83.3% | 13.0% | 1.00 | 2 of 2 |
| [SMH](https://easycompare.io/research/smh): VanEck Semiconductor ETF | 0.39 | +323% | 36.9% | 0.97 | 1 of 2 |
| DBEF: Xtrackers MSCI EAFE Hedged Equity ETF | 0.34 | +85.0% | 13.8% | 0.96 | 1 of 2 |
| [GLD](https://easycompare.io/research/gld): SPDR Gold Shares | 0.12 | +126% | 18.9% | 0.96 | 0 of 2 |
| SPMO: Invesco S&P 500 Momentum ETF | 0.38 | +136% | 20.8% | 0.93 | 1 of 2 |

## Common questions

### What was RVMD's worst drawdown?

RVMD's deepest decline since it began trading in 2020 was 73.3%, from February 2021 to May 2022. It took about two years from the low to climb back to its old high. Because RVMD launched in February 2020, that record does not include the dot-com bust, the 2008 financial crisis or five other sell-offs.

### What were RVMD's best and worst years?

Over five full calendar years, RVMD's best year was 2025, when it returned 82.1%. Its worst was 2021, with a return of -36.4%.

### Is there a better investment than RVMD?

Looking beyond its popular alternatives, KNSA (biotechnology) earned more than RVMD with less volatility over the past 5 years: 50.2% a year at 53.7% volatility, against 48.8% a year at 62.1%. Few investments have done better on both counts: only 27 of the 3,633 stocks and funds worth at least $500 million earned more than RVMD with less volatility over the past 5 years, among them NVDA, MU and DELL.

### Is RVMD more volatile than the S&P 500?

Yes. RVMD's volatility over the past 5 years was 62.1%, 3.6 times the S&P 500's 17.1%. Volatility measures how widely returns swing around their average: in roughly two years out of three, RVMD's return lands within 62.1% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump.

### What is RVMD's Sharpe ratio?

RVMD's Sharpe ratio over the past 5 years was 0.95, against 0.79 for the S&P 500, so RVMD earned more for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings.

### How correlated is RVMD with the S&P 500?

Over the past 5 years, RVMD's monthly returns had a correlation of 0.42 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They often move together: some diversification next to an index fund, but not a cushion. In the table, the correlation column measures each option against RVMD instead: the lower it is, the more that option would diversify a RVMD holding.

### What are the best alternatives to RVMD?

None of the 18 popular alternatives we compared outperformed RVMD in at least 3 of 5 short-term and 2 of 2 long-term timeframes, which says more about RVMD's strength than about its alternatives.

### Did RVMD outperform the S&P 500?

RVMD finished ahead of the S&P 500 (SPY) in three of five full calendar years. In 2025, it returned +82.1%, against +17.7% for the index.

### How did RVMD do in stock market crashes?

RVMD fell less than the S&P 500 (SPY) in none of the three major crashes it has traded through, and further in three. The clearest case was the 2022 bear market, when RVMD fell 46.5% and the S&P 500 fell 24.5%.

### What diversifies RVMD?

These had a low correlation with RVMD over the past 5 years and still earned a positive 5-year return: among large ETFs, LVHI (correlation 0.17), DXJ (correlation 0.19) and EMLP (correlation 0.26); among large stocks, CAH (correlation 0.08), CLS (correlation 0.22) and FIX (correlation 0.39). A correlation near zero means the two have moved largely independently.

## More research

- [Illumina (ILMN) Performance, Alternatives and Market Rank](https://easycompare.io/research/ilmn)
- [Gilead Sciences (GILD) Performance, Alternatives and Market Rank](https://easycompare.io/research/gild)
- [Amgen (AMGN) Performance, Alternatives and Market Rank](https://easycompare.io/research/amgn)
- [Thermo Fisher Scientific (TMO) Performance, Alternatives and Market Rank](https://easycompare.io/research/tmo)
- [Merck & Co., Inc. (MRK) Performance, Alternatives and Market Rank](https://easycompare.io/research/mrk)
- [Schwab U.S. Dividend Equity ETF (SCHD) Performance, Alternatives and Market Rank](https://easycompare.io/research/schd)
- [NVIDIA (NVDA) Performance, Alternatives and Market Rank](https://easycompare.io/research/nvda)
- [Apple (AAPL) Performance, Alternatives and Market Rank](https://easycompare.io/research/aapl)
- [Alphabet (GOOG) Performance, Alternatives and Market Rank](https://easycompare.io/research/goog)
- [Microsoft (MSFT) Performance, Alternatives and Market Rank](https://easycompare.io/research/msft)
- [Amazon.com (AMZN) Performance, Alternatives and Market Rank](https://easycompare.io/research/amzn)
- [Vanguard Morningstar Total Stock Market ETF (VTI) Performance, Alternatives and Market Rank](https://easycompare.io/research/vti)

## Explore further

- Full page with charts: https://easycompare.io/research/rvmd
- All research pages: https://easycompare.io/llms.txt
- Compare the entire market against RVMD live: https://betterthanspy.com/?b=RVMD&utm_source=easycompare&utm_medium=research